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Background:  CD4+CD28nullT-cells are expanded in ACS; they produce large amount of IFNa, and express high levels of TNF-related-apoptosis-
induced ligand (TRAIL) and of IL12 receptor (IL12R), thus predisposing to vascular injury. In contrast, Treg number is reduced in ACS and their 
functional profile, including the production of the anti-inflammatory IL-10, is altered. Objective of this study is to evaluate the ex-vivo effects of 
atorvastatin on T-cell subsets with opposite functions, CD4+CD28nullT-cells and CD4+CD25highT-cells (Treg), in patients with acute coronary 
syndrome (ACS).
Methods:  Peripheral blood samples were collected from 20 statin-naive ACS patients. The function of CD4+CD28nullT-cells and of Treg was 
assessed by flow-cytometry on peripheral blood mononuclear cells incubated for 24 hours with increasing doses of atorvastatin: 3-10-26 μg/ml 
(approximately corresponding to blood levels achieved with doses of 10-40-80 mg, respectively).
Results:  The percentage of CD4+CD28nullT-cells expressing TRAIL and IL12R decreased from a median of 3.0% (range 1.1-13.7) and of 4.7% 
(range 0.8-13.8) (untreated cells) to 1.8% (range 0.6-4.7) and 2.2% (range 0.6-5.1) after incubation with 26 ug/ml atorvastatin (P=0.028 and 
0.027, respectively). Similarly, the percentage of CD4+CD28nullT-cells producing IFNa decreased from a median of 11.5% (range 0.5-40.9) 
(untreated cells) to 5.0% (range 0.1-30.2) after incubation with 26 ug/ml atorvastatin (P=0.009). Finally, the percentage of Treg producing IL10 
increased from a median of 23% (range 4.2-89.8) (untreated cells) to 54.5% (range 19.1-91.7) after incubation with 26 ug/ml atorvastatin 
(P<0.001).
Conclusions:  In ACS, ex-vivo atorvastatin treatment significantly inhibits CD4+CD28nullT-cells while enhances Treg functions, thus resulting in an 
overall powerful anti-inflammatory effect.
